About Halucenex
Halucenex is a company based in Windsor (Canada) founded in 2019 was acquired by Creso Pharma in March 2021. The company has 2 employees as of December 31, 2024. Halucenex operates in a competitive market with competitors including Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Reunion Neuroscience and Cerecor, among others.
- Headquarter Windsor, Canada
- Employees 2 as on 31 Dec, 2024
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
2
as on Dec 31, 2024
-
Acquired by
Creso Pharma
(Mar 15, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Halucenex
Detailed funding history for Halucenex
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Halucenex
Halucenex has secured backing from 1 investor. Prominent investors backing the company include Creso Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Cannabinoid therapeutics are developed for human and veterinary health applications.
|
Locked | Locked | Locked |
Investor details for Halucenex
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Halucenex
Investment portfolio details for Halucenex
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Halucenex
Detailed financials for Halucenex
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Halucenex Comparisons
Peer comparison for Halucenex
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Halucenex
Halucenex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alto Neuroscience, Supernus Pharmaceuticals, Newron Pharmaceuticals, Reunion Neuroscience and Cerecor, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers
|
|
| Locked | Locked | Locked |
Specialty pharmaceutical products for CNS diseases are developed and commercialized.
|
|
| Locked | Locked | Locked |
Therapies for central nervous system diseases and pain are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for mental health conditions are developed using serotonergic psychedelics.
|
|
| Locked | Locked | Locked |
Therapeutics for immunological and neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Neurochemical modulators for ADHD treatment are developed by Neurovance.
|
Detailed competitors of Halucenex
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Halucenex
Complete news archive for Halucenex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Halucenex
Halucenex was founded in 2019.
Halucenex is headquartered in Windsor, Canada. It is registered at Windsor, Ontario, Canada.
As of Dec 31, 2024, the latest employee count at Halucenex is 2.
Founded in 2019 and based in Windsor, Canada, Halucenex is involved in the biotechnology sector, where psychedelic compounds such as psilocybin and its derivatives are developed for addressing PTSD and anxiety. Operations focus on therapeutic applications of these substances, with research exploring their roles in managing depression, addiction, mood disorders, and related conditions through guided psychedelic therapy protocols.
Halucenex's top competitors include Alto Neuroscience, Supernus Pharmaceuticals and Newron Pharmaceuticals.
Halucenex has 1 investor. Key investors include Creso Pharma.